… Introduction:Rivaroxaban is an oral direct factor Xa inhibitor developed for … effects on
common reagents and assay procedures are largely unknown. Objectives:To investigate the effect …

Rivaroxaban (BAY 59‐7939) is an oral, direct factor Xa inhibitor in advanced development.
This study was undertaken to investigate its effects on thrombin generation. In this placebo‐…

… Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of
… , NJ, USA), is one of the newest oral direct FXa inhibitors, with a relative molecular weight of …

… BAY 59–7939 is an oral, direct factor Xa inhibitor in development for the prevention and
treatment of thromboembolic diseases (Fig 2). It is a member of a new class of small–molecule, …

… BAY 59-7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention
and treatment of arterial and venous thrombosis. BAY 59-7939 competitively inhibits human …

… This study evaluated the effects of impaired renal function on the pharmacokinetics,
pharmacodynamics and safety of rivaroxaban (10 mg single dose), an oral, direct Factor Xa inhibitor. …

… of new oral anticoagulants that target either factor Xa or thrombin… apixaban, and edoxaban,
the oral factor Xa inhibitors in the most … Therefore, development of the oral factor Xa inhibitors …

… Food effects are not uncommon and occur because of diverse factors regulating oral
bioavailability and food interaction. For instance, the observed lag time in absorption of …

… There is a clinical need for safe new oral anticoagulants. The safety, tolerability,
pharmacodynamics, and pharmacokinetics of BAY 59-7939—a novel, oral, direct Factor Xa (FXa) …

… Parenteral factor Xa inhibitors promise efficacy comparable to standard therapies,which …
patients with oral agents.We evaluated the antithrombotic effect of the oral,direct factor Xa …